Brief: FDA Directs Takeda To Add Boxed Warning To Adzynma Drug Label
23/09/2026 23:13
BRIEF-FDA Directs Takeda To Add Boxed Warning To Adzynma Drug Label Sept 23 (Reuters) - FDA:
FDA: DIRECTED TAKEDA PHARMACEUTICALS TO ADD BOXED WARNING, ON DRUG LABEL, TO ADZYNMA'S PRESCRIBING INFORMATION
Further company coverage: 4502.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)